<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062317</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0584</org_study_id>
    <nct_id>NCT05062317</nct_id>
  </id_info>
  <brief_title>ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases</brief_title>
  <official_title>Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the detection of ctDNA after surgical resection of CLM can stratify patients&#xD;
      into high and low-risk cohorts for early disease recurrence in order to inform post-operative&#xD;
      adjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • To assess 1-year recurrence-free survival rate following liver resection of CLM with&#xD;
      curative intent among ctDNA-negative patients who receive risk-stratified postoperative&#xD;
      chemotherapy&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess recurrence-free survival following liver resection of CLM with curative intent&#xD;
           among ctDNA-positive patients&#xD;
&#xD;
        -  To assess overall survival following liver resection among ctDNA-negative and&#xD;
           ctDNA-positive patients&#xD;
&#xD;
        -  To evaluate the proportion of ctDNA-negative at 1-year post-resection&#xD;
&#xD;
        -  To compare survival of ctDNA-negative patients undergoing ctDNA-guided postoperative&#xD;
           chemotherapy to historical controls&#xD;
&#xD;
        -  To evaluate proportion of patients in each arm who change chemotherapy in response to&#xD;
           ctDNA measurement&#xD;
&#xD;
        -  To delineate the pattern of disease recurrence&#xD;
&#xD;
        -  To assess ctDNA sensitivity and specificity for predicting disease recurrence&#xD;
&#xD;
        -  To evaluate MDASI-GI during the course of postoperative therapy&#xD;
&#xD;
        -  To evaluate and correlate patient molecular subtypes and characterization of tumor&#xD;
           biologic factors that are associated with ctDNA detection&#xD;
&#xD;
        -  To evaluate surgery-related adverse events occurring up to 90 days after surgery, and&#xD;
           chemo-related adverse events occurring up to 30 days after the last dose of chemotherapy&#xD;
&#xD;
      Outcome Measures:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      • Recurrence-free survival at 1-year post-hepatectomy among ctDNA-negative patients&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Recurrence-free survival at 1-year post-hepatectomy among ctDNA-positive patients&#xD;
&#xD;
        -  Overall survival (OS) among ctDNA-negative and ctDNA-positive patients&#xD;
&#xD;
        -  ctDNA-negativity at 1-year post-resection&#xD;
&#xD;
        -  Proportion of patients in each group with chemotherapy regimen change in response to&#xD;
           ctDNA dynamics&#xD;
&#xD;
        -  Pattern of disease recurrence (i.e., liver, systemic, salvageable vs. unsalvageable)&#xD;
&#xD;
        -  ctDNA sensitivity/specificity for recurrent disease overall by timepoint&#xD;
&#xD;
        -  MDASI-GI at clinic visits during course of postoperative therapy&#xD;
&#xD;
        -  Tumor radiologic, histologic, and molecular profiling and correlative characterization&#xD;
           based upon ctDNA detection&#xD;
&#xD;
        -  Adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>ctDNA (Low Risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX [5-fluorouracil, leucovorin and oxaliplatin] or FOLFIRI [5-fluorouracil, leucovorin and irinotecan] with or without bevacizumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given by PO</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
    <arm_group_label>ctDNA (Low Risk)</arm_group_label>
    <other_name>Citrovorum</other_name>
    <other_name>Wellcovorin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FLUOROURACIL</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given by PO</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
    <arm_group_label>ctDNA (Low Risk)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>ctDNA (High Risk)</arm_group_label>
    <other_name>Avastin™</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative&#xD;
             intent (primary colorectal primary cancer previously removed OR being removed at time&#xD;
             of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab&#xD;
             or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023&#xD;
&#xD;
          -  Must receive ≥ 4 cycles of preoperative chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary colorectal tumor that will remain in situ&#xD;
&#xD;
          -  Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not&#xD;
             planned a priori&#xD;
&#xD;
          -  Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined&#xD;
&#xD;
          -  Other active malignancies requiring treatment&#xD;
&#xD;
          -  Women who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Newhook</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Newhook</last_name>
    <phone>(713) 794-1001</phone>
    <email>tnewhook@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Timothy Newhook</last_name>
      <phone>713-794-1001</phone>
      <email>tnewhook@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Newhook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

